Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 5/20 | 0.38 |
| ▸ | P2RX7 | Q99572 | 3/20 | 0.31 |
| ▸ | BMPR1B | O00238 | 1/20 | 0.30 |
| ▸ | BMPR1A | P36894 | 1/20 | 0.30 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.30 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.30 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13675751 | 0.89 | HSD11B1 (0.40) | HSD11B1P2RX7 | |
| SCHEMBL4521367 | 0.81 | HSD11B1 (0.37) | HSD11B1P2RX7ACVR1 | |
| SCHEMBL4502408 | 0.79 | HSD11B1 (0.39) | HSD11B1P2RX7BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL13674545 | 0.78 | HSD11B1 (0.38) | HSD11B1P2RX7BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL4514504 | 0.78 | HSD11B1 (0.38) | HSD11B1P2RX7BMPR1BBMPR1ATGFBR1 | |
| SCHEMBL3001590 | 0.78 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL13674486 | 0.78 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL3001587 | 0.78 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL3001594 | 0.78 | P2RX7 (0.42) | HSD11B1P2RX7 | |
| SCHEMBL4512739 | 0.78 | HSD11B1 (0.46) | HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264650-A1 | Prophylactic/Therapeutic Agent for Diabetes | HSD11B1, HSD17B1, HSD11B2 | HSD11B1 1/4885P2RX7 3946/4885BMPR1B 3003/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.